NCT00947102

Brief Summary

Observational study of influence of gemcitabine treatment on serological and immunological status and gene expression profile in patients with pancreatic tubular carcinoma after tumor resection.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Feb 2009

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2009

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

July 24, 2009

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 27, 2009

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2011

Completed
Last Updated

January 13, 2010

Status Verified

July 1, 2009

Enrollment Period

2.8 years

First QC Date

July 24, 2009

Last Update Submit

January 12, 2010

Conditions

Pancreatic Tubular Adenocarcinoma

Keywords

pancreatic tubular adenocarcinomagemcitabinegene expressionimmunological statusserological statuspancreatic tubular adenocarcinoma adjuvant setting

Study Arms (1)

Pancreatic tubular adenocarcinoma

Patients with pancreatic tubular adenocarcinoma

Other: Observation

Interventions

ObservationOTHER
Pancreatic tubular adenocarcinoma

Eligibility Criteria

Age30 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients after resection of pancreatic tubular adenocarcinoma

You may qualify if:

  • Following R0 or R1 pancreatic tubular adenocarcinoma resection

You may not qualify if:

  • Pregnancy
  • Serious comorbidity

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Medical Centre Ljubljana; Department for Gastroenterology

Ljubljana, Ljubljana, 1000, Slovenia

RECRUITING

MeSH Terms

Interventions

Observation

Intervention Hierarchy (Ancestors)

MethodsInvestigative Techniques

Central Study Contacts

Borut Stabuc, MD, PhD

CONTACT

+386 1 522 22 10borut.stabuc@kclj.si

Lojze Smid, MD

CONTACT

lojze.smid.jr@mf.uni-lj.si

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

July 24, 2009

First Posted

July 27, 2009

Study Start

February 1, 2009

Primary Completion

December 1, 2011

Study Completion

December 1, 2011

Last Updated

January 13, 2010

Record last verified: 2009-07

Locations

SL(1)